Cadazolid - CAS 1025097-10-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Cadazolid, also referred to ACT-179811,is a new fluoroquinolone-oxazolidinone antibiotic with potent activity against Clostridium difficile.
Brife Description:
A novel fluoroquinolone-oxazolidinone antibiotic with potent activity against Clostridium difficile
1-Cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid; ACT-179811; ACT 179811; ACT179811; Cadazolid
DMSO: ≥150 mg/mL
Store in a cool and dry place (or refer to the Certificate of Analysis).
Boiling Point:
832.6±65.0 ℃
1.539±0.06 g/cm3
Canonical SMILES:
1.Novel Antimicrobials for the Treatment of
Petrosillo N;Granata G;Cataldo MA Front Med (Lausanne). 2018 Apr 16;5:96. doi: 10.3389/fmed.2018.00096. eCollection 2018.
The current picture of ;Clostridium difficile; infection (CDI) is alarming with a mortality rate ranging between 3% and 15% and a CDI recurrence rate ranging from 12% to 40%. Despite the great efforts made over the past 10 years to face the CDI burden, there are still gray areas in our knowledge on CDI management. The traditional anti-CDI antimicrobials are not always adequate in addressing the current needs in CDI management. The aim of our review is to give an update on novel antimicrobials for the treatment of CDI, considering the currently available evidences on their efficacy, safety, molecular mechanism of action, and their probability to be successfully introduced into the clinical practice in the near future. We identified, through a PubMed search, 16 novel antimicrobial molecules under study for CDI treatment: cadazolid, surotomycin, ridinilazole, LFF571, ramoplanin, CRS3123, fusidic acid, nitazoxanide, rifampin, rifaximin, tigecycline, auranofin, NVB302, thuricin CD, lacticin 3147, and acyldepsipeptide antimicrobials. In comparison with the traditional anti-CDI antimicrobial treatment, some of the novel antimicrobials reviewed in this study offer several advantages, i.e., the favorable pharmacokinetic and pharmacodynamic profile, the narrow-spectrum activity against CD that implicates a low impact on the gut microbiota composition, the inhibitory activity on CD sporulation and toxins production.
2.[New antibacterial agents on the market and in the pipeline].
Kern WV Internist (Berl). 2015 Nov;56(11):1255-63.
After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of these new developments have been in conventional antibacterial classes. New drugs among the beta-lactam agents are methicillin-resistant Staphylococcus aureus (MRSA) active cephalosporins (ceftaroline and ceftobiprole) and new combinations of beta-lactam with beta-lactamase inhibitors (ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam and meropenem/RPX7009). New developments can also be observed among oxazolidinones (tedizolid, radezolid, cadazolid and MRX-I), macrolides/ketolides (modithromycin and solithromycin), aminoglycosides (plazomicin), quinolones (nemonoxacin, delafloxacin and avarofloxacin), tetracyclines (omadacycline and eravacycline) as well as among glycopeptides and lipopeptides (oritavancin, telavancin, dalbavancin and surotomycin). New agents in a very early developmental phase are FabI inhibitors, endolysines, peptidomimetics, lipid A inhibitors, methionyl-tRNA synthetase inhibitors and teixobactin.
3.[Treatment of acute and recurrent Clostridium difficile infections : What is new?]
von Braun A;Lübbert C Internist (Berl). 2018 May;59(5):505-513. doi: 10.1007/s00108-018-0401-x.
The incidence of clostridium difficile infections (CDI) remains on a high level globally. In Germany, the number of severe or even lethal cases continues to increase. The main risk factor for the development of CDI is exposure to broad spectrum antibiotics, which disturb the physiological microbiome and therefore enable colonization with C. difficile. According to the updated US and European guidelines, orally administered vancomycin is the treatment of choice. Fidaxomicin is as effective as vancomycin but has the advantage of a lower rate of recurrence. Furthermore, recent clinical studies were able to demonstrate that significantly fewer recurrences occurred in patients who additionally received the monoclonal antibody bezlotoxumab. In recent years, several new antibiotics with narrow-spectrum acitivity and low intestinal resorption have been developed for the treatment of CDI, including surotomycin, cadazolid, and ridinilazol. Novel toxoid vaccines are expected to become an efficacious tool in the prevention of CDI; however, pivotal clinical trials have so far not been completed.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products

CAS 1196800-40-4 Omadacycline mesylate

Omadacycline mesylate
(CAS: 1196800-40-4)

Omadacycline mesylate is a new tetracycline antibiotic in the pipeline, which can inhibit the 30s subunit of bacterial ribosome.

CAS 122841-10-5 Cefoselis

(CAS: 122841-10-5)

Cefoselis, a new parenteral cephalosporin, was active against clinical isolates of both gram-positive and gram-negative aerobic bacteria. The activity of Cefose...

CAS 186826-86-8 Moxifloxacin HCl

Moxifloxacin HCl
(CAS: 186826-86-8)

Moxifloxacin exerts its effects by trapping a DNA drug enzyme complex and specifically inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisom...

CAS 856866-72-3 Tedizolid

(CAS: 856866-72-3)

Torezolid is a novel oxazolidinone for gram-positive infections. It was reversible inhibitors of human MAO-A and MAO-B.

CAS 70458-96-7 Norfloxacin

(CAS: 70458-96-7)

Norfloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria, which functions by inhibiting DNA gyrase. It is...

CAS 9001-63-2 Lysozyme

(CAS: 9001-63-2)

Lysozyme is an antimicrobial enzyme produced by animals, damaging bacterial cell walls via hydrolysis between residues in peptidoglycan walls.

BMS 180680
(CAS: 142654-34-0)

BMS 180680 is antibacterial activity agent of new catechol-containing monobactam. It is a cell wall inhibitor. BMS-180680 is an active compound against many spe...

CAS 119478-56-7 Meropenem trihydrate

Meropenem trihydrate
(CAS: 119478-56-7)

Meropenem (trihydrate) is a carbapenem antibiotic, which displaying a broad spectrum of antibacterial activity.

Chemical Structure

CAS 1025097-10-2 Cadazolid

Quick Inquiry

Verification code

Featured Items